Predicting the effectiveness of prevention: A role for epidemiological modeling

Journal of Primary Prevention

Volumn 29, Issue 4, 2008, Pages 295-305

  Walls, Helen L ^a   Peeters, Anna ^a   Reid, Christopher M ^a   Liew, Danny ^b   McNeil, John J ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Epidemiological modelling; Health policy; Prevention; Prioritisation

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN;

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROMOTION; HUMAN; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREVENTIVE MEDICINE; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SURVIVAL RATE;

EPIDEMIOLOGIC METHODS; HEALTH CARE COSTS; HEALTH POLICY; HEALTH PRIORITIES; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PRIMARY PREVENTION;

EID: 48249130436     PISSN: 0278095X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10935-008-0143-y     Document Type: Article

References (29)

1. JJ Barendregt L Bonneux PJ Van Der Maas 1997 The health care costs of smoking New England Journal of Medicine 337 1052 1057
2. VM Beir 2001 On the state of the art: Risk communication to the public Reliability Engineering and System Safety 71 139 150
3. M Brandeau G Zaric V De Angelis 2005 Improved allocation of HIV prevention resources: Using information about prevention program production functions Health Care Management Science 8 19 28
4. E Doran D Henry 2006 Pharmaceutical benefits scheme policy: Confused and tough on patients Internal Medicine Journal 36 211 213
5. A Edwards G Elwyn A Mulley 2002 Explaining risks: Turning numerical data into meaningful pictures British Medical Journal 324 827 830
6. ES Ford UA Ajani JB Croft J Critchely DR Labarthe TE Kottke 2007 Explaining the decrease in U.S. deaths from coronary disease, 1980-2000 New England Journal of Medicine 356 2388
7. OH Franco A Peeters CW Looman L Bonneux 2005 Cost effectiveness of statins in coronary heart disease Journal of Epidemiology and Community Health 59 927 933
8. JF Fries 1980 Aging, natural death, and the compression of morbidity New England Journal of Medicine 303 130 135
9. Haddix, A., Teutsch, S. M., & Corso, P. S. (2003). Prevention effectiveness: A guide to decision analysis and economic evaluation, (2nd ed., pp. 264). Oxford: Oxford University Press. ISBN: 0-19-514897-5.
10. R Jackson 2001 Are the new lipid management guidelines good for Australia's health? Medical Journal of Australia 175 452 453
11. K Johnson M Lassere 2003 Letters-Epidemiological modelling (including economic modelling) and its role in preventive drug therapy Medical Journal of Australia 178 188
12. D Liew J McNeil A Peeters S Lim T Vos 2002 Epidemiological modelling (including economic modelling) and its role in preventive drug therapy Medical Journal of Australia 177 364 367
13. S Lim T Vos A Peeters D Liew J McNeil 2001 Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria Medical Journal of Australia 175 459 464
14. Malenka, D. J., Baron, J. A., Johansen, S., Wahrenberger, J. W., & Ross, J. (1993). The framing effect of relative and absolute risk. Journal of General Internal Medicine, 8, 543-548.
15. AA Mamun A Peeters JJ Barendregt F Willekens WJ Nusselder L Bonneux 2004 Smoking decreases the duration of life lived with and without cardiovascular disease: A life course analysis of the Framingham heart study European Heart Journal 25 409 415
16. T Marshall 2003 Coronary heart disease prevention: Insights from modelling incremental cost effectiveness British Medical Journal 327 1264 1275
17. Mathers, C. D., & Loncar, D. (2005). Updated projections of global mortality and burden of disease, 2002-2030: Data sources, methods and results. Evidence and information for policy. Geneva: World Health Organization.
18. P McEwan JR Peters K Bergenheim CJ Currie 2006 Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) Current Medical Research Opinion 22 121 129
19. J McNeil A Peeters D Liew S Lim T Vos 2001 A model for predicting the future incidence of coronary heart disease within percentiles of coronary heart disease risk Journal of Cardiovascular Risk 8 31 37
20. CJL Murray AD Lopez 1997 Mortality by cause for eight regions of the world: Global burden of disease study The Lancet 349 1269 1276
21. M Nelson D Liew M Bertram T Vos 2005 Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70 British Medical Journal 327 1 6
22. A Peeters L Bonneaux JJ Barendregt JP Mackenbach 2003 Improvements in treatment of coronary heart disease and cessation of stroke mortality rate decline American Stroke Association 34 1610 1614
23. R Pike A Keech R Simes 2003 Clinical trials research in the new millennium: The International Clinical Trials Symposium, Sydney, 21-23 October 2002 Medical Journal of Australia 178 316 317
24. Reid, C., Meehan, A., Owen, A., Wlodarczyk, J., Robb, T., Hardy, M., et al. (2006). The Bosentan patient registry. In Proceedings of the National Medicines Symposium, Canberra, AU.
25. R Simes 2002 Clinical trails and "real-world" medicine Medical Journal of Australia 177 410 411
26. G Simon E Wagner M Vonkorff 1995 Cost-effectiveness comparisons using "real-world" randomized trials: The case of new antidepressant drugs Journal of Clinical Epidemiology 48 363 373
27. N Stocks J Allan PR Mansfield 2005 Management of hyperlipidaemia Australian Family Physician 34 447 453
28. B Unal S Capewell JA Critchley 2006 Coronary heart disease policy models: A systematic review BMC Public Health 6 213
29. P Zhang MM Engelgau SL Norris EW Gregg KMV Narayan 2004 Application of economic analysis to diabetes and diabetes care Annals of Internal Medicine 140 972 977